Raquel Laza‐Briviesca

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 828 citations

Medicine, Oncology, Pharmacology +14

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2019 · 215 citations · Full text

Medicine, Oncology, Pharmacology +16

Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2018 · 140 citations · Full text

Medicine, Cancer Biology, Oncology +17

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Marta Casarrubios, Alberto Cruz‐Bermúdez, Ernest Nadal et al. · Clinical Cancer Research · 2021 · 67 citations · Full text

Life Sciences, Immunology, Oncology +17

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal et al. · Clinical and Translational Medicine · 2021 · 56 citations · Full text

Medicine, Immunology, Oncology +17